Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pituitary
Published in: Pituitary 4/2010

01-12-2010

Acquired resistance to cabergoline: progression from initially responsive micro to macroprolactinoma

Authors: M. Alberiche Ruano, M. Boronat Cortés, A. Ojeda Pino, C. Rodriguez Perez, M. Gracía Nuñez, D. Marrero Arencibia, F. J. Novoa Mogollón

Published in: Pituitary | Issue 4/2010

Login to get access

Excerpt

In a recent issue of this Journal, Behan et al. [1] published a case of secondary resistance to cabergoline in a patient with prolactinoma. We communicate another case of this exceptional circumstance. …
Literature
1.
Behan LA, Draman MS, Moran C, King T, Crowley RK, O’Sullivan EP et al (2009) Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary Feb 4 (Epub ahead of print)
2.
Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R et al (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Met 86:5256–5261CrossRef
3.
Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M et al (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24. month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Met 89:1704–1711CrossRef
4.
Olafsdottir A, Schlecht J (2006) Management of resistant prolactinomas. Nat Clin Pract Endocrinol Metab 2:552–561CrossRefPubMed
5.
Filopanti M, Barbieri AM, Angioni AR, Colao A, Gasco V, Grottoli S et al (2008) Dopamine D2 receptor gene polymorphism and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Pharmacogenomics J 8:353–363CrossRef
6.
Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP et al (1989) Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Met 69:500–509CrossRef
7.
Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, Jaquet P et al (1994) Decrease expression of the two D2 dopamine receptor isoforms in bromocriptin resistant prolactinomas. Neuroendocrinology 60:314–322CrossRefPubMed
8.
Nawar RN, AbdelMannan D, Selman WR, Arafah BM (2008) Analytic review: pituitary tumor apoplexy: a review. J Intensive Care Med 23:75–90CrossRefPubMed
9.
Biller BMK, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA et al (1996) Treatment of prolactin-secreting macroadenomas with once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81:2338–2343CrossRefPubMed
10.
Knoepfelmacher M, Gomes MC, Melo ME, Mendonca BB (2004) Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma. Pituitary 7:83–87CrossRefPubMed
11.
Ishay A, Levahar P, Qupty G (2004) Expansion of intratumoral hemorrhage in a patient with macroprolactinoma treated with cabergoline. Endocrinologist 14:126–128CrossRef
Metadata
Title
Acquired resistance to cabergoline: progression from initially responsive micro to macroprolactinoma
Authors
M. Alberiche Ruano
M. Boronat Cortés
A. Ojeda Pino
C. Rodriguez Perez
M. Gracía Nuñez
D. Marrero Arencibia
F. J. Novoa Mogollón
Publication date
01-12-2010
Publisher
Springer US
Published in
Pituitary / Issue 4/2010
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-010-0237-4

Other articles of this Issue 4/2010

Pituitary 4/2010 Go to the issue

OriginalPaper

Cardiac effects of 3 months treatment of acromegaly evaluated by magnetic resonance imaging and B-type natriuretic peptides

OriginalPaper

The clinical significance of MIB-1 labeling index in pituitary adenomas

OriginalPaper

The elusive Minnie G.: revisiting Cushing’s case XLV, and his early attempts at improving quality of life

OriginalPaper

Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release in hyperthyroidism before and after treatment

OriginalPaper

Oral estroprogestin: an alternative low cost therapy for women with postoperative persistent acromegaly?

Case Report

Primary pituitary abscess followed by empty sella syndrome in an adolescent girl
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits